Walleye Capital’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.94M Buy
274,173
+262,871
+2,326% +$9.11M 0.01% 1365
2026
Q2
$441K Buy
11,302
+6,729
+147% +$217K ﹤0.01% 2858
2026
Q1
$149K Sell
4,573
-81,798
-95% -$2.63M ﹤0.01% 3499
2025
Q4
$3.04M Buy
86,371
+30,113
+54% +$1.07M 0.01% 1520
2025
Q3
$1.48M Buy
56,258
+54,625
+3,345% +$1.63M 0.01% 1796
2025
Q2
$43.3K Sell
1,633
-33,866
-95% -$892K ﹤0.01% 4081
2025
Q1
$857K Buy
35,499
+34,799
+4,971% +$1.1M ﹤0.01% 2102
2024
Q4
$28.2K Sell
700
-7,139
-91% -$407K ﹤0.01% 4455
2024
Q3
$496K Buy
7,839
+1,655
+27% +$97.1K ﹤0.01% 3309
2024
Q2
$328K Sell
6,184
-10,016
-62% -$657K ﹤0.01% 3902
2024
Q1
$1.33M Buy
+16,200
New +$721K ﹤0.01% 2314
2023
Q3
– Sell
-81,251
Closed -$1.32M – 5357
2023
Q2
$1.32M Buy
81,251
+38,187
+89% +$800K ﹤0.01% 1625
2023
Q1
$717K Sell
43,064
-170,247
-80% -$1.76M 0.01% 1400
2022
Q4
$2.01M Sell
213,311
-885,019
-81% -$3.95M 0.04% 578
2022
Q3
$2.99M Buy
1,098,330
+802,330
+271% +$2.63M 0.06% 368
2022
Q2
$855K Buy
296,000
+218,982
+284% +$542K 0.02% 728
2022
Q1
$231K Buy
+77,018
New +$276K 0.01% 1441
2020
Q1
– Sell
-22,736
Closed -$182K – 1716
2019
Q4
$182K Buy
+22,736
New +$166K 0.01% 1149
2018
Q3
$306K Buy
+17,574
New +$209K 0.14% 175

Other funds holding VKTX

Walleye Capital's VKTX Position: Q3 2026 in Review

Walleye Capital increased its Viking Therapeutics (VKTX) stake by 2,326% in Q3 2026, buying an estimated $9.11M and bringing the position to 274,173 shares worth $8.94M. The position accounts for 0.01% of the portfolio, ranked #1365.

Walleye Capital first reported a position in VKTX in Q3 2018 and has held it in 19 quarters since. 439 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Walleye Capital held 274,173 shares of Viking Therapeutics worth $8.94M as of Q3 2026.
  • Walleye Capital bought 262,871 Viking Therapeutics shares in Q3 2026, an estimated $9.11M.
  • Viking Therapeutics made up 0.01% of Walleye Capital's portfolio in Q3 2026, its #1365 holding.
  • Walleye Capital first reported a position in Viking Therapeutics in Q3 2018 and has held it in 19 quarters since.
  • 439 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.